Episodios

  • Wrap Up

    Wrap Up
    Nov 19 2024
    2 m
  • Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT

    Long-Term Safety and Efficacy of Zilucoplan in Generalized Myasthenia Gravis 120-Week Interim Analysis of RAISE-XT
    Nov 19 2024

    Author: Howard, JF, et al.
    Overview Provided by Nicolas Silvestri, MD

    Más Menos
    3 m
  • Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study

    Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 VIVACITY-MG3 Study
    Nov 19 2024

    Author: Strober J, et al.
    Overview Provided by Nicolas Silvestri, MD

    Más Menos
    3 m
  • Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results

    Concomitant Corticosteroid Use with Ravulizumab in Adults with Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Phase 3 CHAMPION-MG Open-Label Extension Final Results
    Nov 19 2024

    Author: Nicolle M, et al.
    Overview Provided by Nicolas Silvestri, MD

    Más Menos
    3 m
  • Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT

    Cyclic and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
    Nov 19 2024

    Author: Habib AA, et al
    Overview Provided by Nicolas Silvestri, MD

    Más Menos
    3 m
  • Introduction

    Introduction
    Nov 19 2024
    2 m